Since its establishment in 2008, The CDE Health Technology Assessment division (HTA team) has been providing evidence-based health technology assessment services as commissioned by the competent authority. The mission of the HTA division is to establish a transparent and scientific HTA system in Taiwan.
The main task of the HTA team is to assist the NHIA of the MOHW in performing effectiveness and economic assessments on new drugs and new medical devices (including comparative clinical effectiveness, cost effectiveness and budget impact), searching and summarizing scientific evidences, the applicability in Taiwan, etc. The assessment reports made by the HTA team serve as foundations for the NHIA’s decision-making process on listing new drugs and new medical devices. In addition to the tasks regarding to NHI reimbursement decisions on new drugs and new medical devices, the HTA team also accepts commissions from other health authorities in MOHW (such as the Health Promotion Administration, the Centers for Disease Control, etc.) to conduct various HTA projects.